Gal-3 is an important receptor for advanced glycation end products (RAGEs) on the cell surface, and it has been suggested that pharmacological inhibition of AGE receptor-mediated cell activation with specific antagonists may provide the basis for therapeutic interventions in these diseases (Pugliese et al., 2015), along with the impact of ligand glycoconjugates which influence Gal-3 binding and may modulate inflammatory responses and remyelination in neurodegenerative diseases (Nio-Kobayashi and Itabashi, 2021). The gene discussed is LGALS3; the disease is neurodegenerative disease.